Advanced Malignant Glioma
Conditions
Keywords
Glioma, Brain Tumor
Brief summary
The purpose of this study is to evaluate the effectiveness and safety of AMG 102 for the treatment of Advanced Malignant Glioma.
Interventions
AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
Sponsors
Amgen
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* subjects with documented histologically confirmed primary grade 4 advanced malignant glioma * no more than 3 prior relapses or prior systemic treatments * recurrent disease documented by MRI after prior therapy * must have at least one site of bidimensionally measurable disease: * archived tissue from the initial diagnosis of advanced malignant glioma or upon transformation to advanced malignant glioma are available for central review within approximately 4 weeks after enrollment * age ≥ 18 years * Karnofsky performance score ≥ 60% * hemoglobin ≥ 10 g/dL * absolute neutrophil count ≥ 1.5 x 10(9th)/L * platelet count ≥ 100 x 10(9th)/L * serum creatinine ≤ 1.5 times upper limit of normal * alanine aminotransferase ≤ 2.5 times upper limit of normal * serum total bilirubin ≤ 2.5 times upper limit of normal * before any study-specific procedure, the appropriate written informed consent must be obtained
Exclusion criteria
* history of central nervous system bleeding as defined by stroke or intraocular bleed (including embolic stroke) within 6 months before enrollment * evidence of acute intracranial/intratumoral hemorrhage; except for subjects with stable grade 1 hemorrhage * received radiation therapy within 4 weeks before enrollment or have not recovered from the toxic effects of such therapy * treated previously with any c-Met or HGF targeted therapy * treated with thalidomide or tamoxifen within 1 week before enrollment or has not recovered from the toxic effects of such cancer therapy * treated with immunotherapeutic agents, vaccines or mAb therapy within 4 weeks before enrollment or have not recovered from the toxic effects of such cancer therapy * treated with alkylating agents within 4 weeks before enrollment or has not recovered from the toxic effects of such cancer therapy * treated with chemotherapy (non-alkylating agents) within 2 weeks before enrollment or has not recovered from the toxic effects of such cancer therapy * surgical resection of brain tumor within 4 weeks before enrollment or have not recovered from acute side effects of such therapy, except for neurological effects * plans to receive surgery, radiation therapy or other elective surgeries during the course of the study * concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes, congestive cardiac failure, myocardial infarction within 6 months before enrollment) that could compromise participation in the study * active infection within 7 days before enrollment * past or current history of another neoplasm, except for curatively treated non-melanoma skin cancer, carcinoma in situ of the cervix and other primary solid cancer with no known active disease present and no curative or adjuvant treatment administered for the last 3 years * documented history of human immunodeficiency virus * documented history of chronic viral hepatitis * concurrent or prior (within 7 days of enrollment) anticoagulation therapy, except: * Use of low molecular weight heparins (LMWH, e.g., enoxaparin sodium \[Lovenox\] and unfractionated heparin for prophylaxis against central venous catheter thrombosis is allowed * Use of low dose warfarin (\< 2 mg/day) for prophylaxis against central venous catheter thrombosis is allowed * currently enrolled in or has not yet completed at least 30 days since ending other investigational device or therapeutic study(s) * had major surgery within 4 weeks before enrollment or recovering from prior surgery * known allergy or sensitivity to any of the excipients in the investigational product * pregnant or breast feeding * unwilling to use adequate contraceptive precautions during the course of the study and for 6 months after the last administration of investigational product, for: * male subjects * female subjects who are not post-menopausal (no menstrual period for a minimum of 12 months at study entry) or documented surgically sterile will not be bound to this exclusion * previously treated with AMG 102 * previously enrolled into this study * will not be available for follow-up assessment * has other disorders that compromises the ability of the subject to give written informed consent and/or comply with study procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assess best objective confirmed response rate in subjects with advanced malignant glioma receiving AMG 102 treatment | Week 9 from first dose of AMG 102 |
Secondary
| Measure | Time frame |
|---|---|
| To assess the safety profile of AMG 102 in subjects with advanced malignant glioma | entire study |
| Estimate overall survival and progression-free survival rates in this population | 8 week intervals |
| Assess the duration of response and time to response in this population | Treatment Period |
| Assess the pharmacokinetics of AMG 102 in subjects with advanced malignant glioma | Weeks 1, 5, and 9 |
Outcome results
None listed